What Makes IQVIA Holdings (IQV) an Investment Bet?

In its first-quarter 2026 capitalist letter, Artisan Value Fund highlighted IQVIA Holdings Inc. (NYSE:IQV) arsenic a recently added position. IQVIA Holdings Inc. (NYSE:IQV) is simply a US-based supplier of objective probe services, commercialized insights, and healthcare quality to the beingness sciences and healthcare industries. On May 22, 2026, IQVIA Holdings Inc. (NYSE:IQV) closed astatine $167.90 per share. One-month instrumentality of IQVIA Holdings Inc. (NYSE:IQV) was 2.48%, and its shares gained 22.55% implicit the past 52 weeks. IQVIA Holdings Inc. (NYSE:IQV) has a marketplace capitalization of $28.02 billion.

Artisan Value Fund stated the pursuing regarding IQVIA Holdings Inc. (NYSE:IQV) successful its Q1 2026 capitalist letter:

"We initiated 4 caller positions successful Q1, an above-average gait of activity. Typically, we adhd 1–2 caller positions per quarter, averaging 1.7 per 4th implicit the past 5 years. Increased marketplace volatility and greater dispersion successful US equities created much opportunities to put successful companies that conscionable our 3 borderline of information criteria: charismatic concern economics, dependable fiscal information and compelling valuation. We besides utilized the accrued volatility to upgrade wide portfolio quality. Our 3 largest caller positions were Amazon.com, Universal Music Group (UMG) and IQVIA Holdings.

IQVIA Holdings Inc. (NYSE:IQV) combines a starring planetary declaration probe enactment (CRO) franchise with a unique, mission-critical wellness attraction information asset, creating a diversified exemplary with some cyclical and recurring gross streams. We judge its Technology & Analytics Solutions segment—anchored by proprietary medicine and diligent data—provides a durable competitory moat, profoundly embedded successful pharma workflows, portion the CRO concern benefits from scale, semipermanent outsourcing trends and analyzable proceedings demand. From a concern prime perspective, IQVIA has generated important escaped currency travel and maintained beardown competitory positioning, supported by precocious lawsuit retention and mission-critical offerings. While leverage is elevated, the company’s currency travel illustration and liquidity supply fiscal flexibility accordant with the team’s accent connected equilibrium expanse resilience and downside protection. Recent stock terms weakness—down materially twelvemonth to date—has been driven by concerns astir AI disruption and softness successful CRO demand, including proceedings cancellations and pharma reprioritization. However, these pressures look cyclical and, successful the lawsuit of AI, apt overstated fixed IQVIA’s proprietary information assets and domain expertise, which are hard to replicate and presumption the institution arsenic a imaginable beneficiary of AI adoption alternatively than a casualty. At 15X guardant net and a high-single-digit escaped currency travel yield, the banal reflects debased expectations contempt resilient fundamentals. Consistent with the team’s process, this dislocation, driven by near-term uncertainty, presents a compelling introduction point, peculiarly if the underlying concern proves much resilient than existent expectations imply."